IDEGLIRA IMPROVES HEALTH UTILITY COMPARED WITH INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE
Author(s)
Freemantle N1, Lingvay I2, Kongsø JH3, Abrahamsen TJ4, Bjorner JB5
1University College London, London, UK, 2UT Southwestern Medical Center, Dallas, TX, USA, 3Novo Nordisk A/S, Bagsvaerd, Denmark, 4Novo Nordisk A/S, Søborg, Denmark, 5University of Copenhagen, Copenhagen, Denmark
OBJECTIVES: This analysis of data from the DUAL V clinical trial compared health utility scores of IDegLira, a fixed-ratio combination of insulin degludec and liraglutide, with insulin glargine (IGlar) in patients with type 2 diabetes (T2D). METHODS: Health status data were collected using the Short-Form 36 v2 (SF-36) questionnaire during a 26-week, multinational, multi-centre, open-label, parallel, randomised, treat-to-target trial comparing IDegLira (n=278) with IGlar (n=279) (either treatment given once daily in addition to metformin) in patients with T2D, inadequately controlled on IGlar (20–50 units daily) and metformin (Buse et al
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PDB95
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Diabetes/Endocrine/Metabolic Disorders